“I’m thrilled with our team’s continued operational and clinical execution prowess that keeps us on track to deliver preliminary data from our ongoing Phase 1 trial of PYX-201, a first-in-concept tumor stroma targeting antibody-drug conjugate (ADC) against the stromal Extradomain-B Fibronectin (EDB+FN) target, this fall,” said Lara S. Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYXS:
- Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
- Is PYXS a Buy, Before Earnings?
- Pyxis Oncology initiated with a Buy at Stifel
- Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference
- 3 Best Stocks to Buy Now, 7/29/2024, According to Top Analysts